ADAPY on OTC

Adaptimmune (United Kingdom)

Logo: adaptimmune.com3

Company in Abingdon, United Kingdom.1

Price unavailable

Last updated Oct 16, 2026.

Overview

2008Founded1

Compare with REGENXBIO Inc., Ginkgo Bioworks or Maze Therapeutics, Inc., or pick any stock.

  • TickerADAPY on OTC1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersAbingdon-on-Thames1
  • Websitewww.adaptimmune.com
  • Incorporated inUnited Kingdom4
  • Business address60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire4
  • Filer categoryNon-accelerated filer, Smaller reporting company4

See how the biggest companies compare on our leaderboards

Adaptimmune (United Kingdom) image from its website
Image: adaptimmune.com3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-38.6%Operating margin5
-39.8%Net margin5
195.3%Revenue growth, 20245
-597.6%Return on equity5
4.24×Debt to equity5
-$74.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue0¢$70.0K
  • Research and development62¢$149.1M
  • Selling, general and admin36¢$87.3M
  • Income tax1¢$3.6M

Out of $178.0M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$178.0M in 2024+199% since 2018
0$50.0M$100.0M$150.0M$200.0M2018: $59.5M$59.5M20182019: $1.1M$1.1M2019−98%2020: $4.0M$4.0M2020+253%2021: $6.1M$6.1M2021+55%2022: $27.1M$27.1M2022+342%2023: $60.3M$60.3M2023+122%2024: $178.0M$178.0M2024+195%
Operating income67895-$68.8M in 2024−17% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$82.4M-$82.4M20182019: -$139.8M-$139.8M2019+70%2020: -$133.4M-$133.4M2020−5%2021: -$162.2M-$162.2M2021+22%2022: -$164.0M-$164.0M2022+1%2023: -$139.7M-$139.7M2023−15%2024: -$68.8M-$68.8M2024−51%
Net income67895-$70.8M in 2024−26% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$95.5M-$95.5M20182019: -$137.2M-$137.2M2019+44%2020: -$130.1M-$130.1M2020−5%2021: -$158.1M-$158.1M2021+22%2022: -$165.5M-$165.5M2022+5%2023: -$113.9M-$113.9M2023−31%2024: -$70.8M-$70.8M2024−38%
Fiscal year2018201920202021202220232024
Revenue$59.5M6$1.1M7$4.0M8$6.1M9$27.1M5$60.3M5$178.0M5
Cost of revenue$70.0K5
Research and development$98.3M6$97.5M7$91.6M8$111.1M9$127.7M5$126.5M5$149.1M5
Selling, general and admin$63.4M5$73.5M5$87.3M5
Operating income-$82.4M6-$139.8M7-$133.4M8-$162.2M9-$164.0M5-$139.7M5-$68.8M5
Income tax$497.0K6$242.0K7$162.0K8$791.0K9$2.5M5$1.3M5$3.6M5
Net income-$95.5M6-$137.2M7-$130.1M8-$158.1M9-$165.5M5-$113.9M5-$70.8M5
Earnings per share-$0.227-$0.158-$0.179-$0.175-$0.095-$0.055
Earnings per share (diluted)-$0.227-$0.158-$0.179-$0.175-$0.095-$0.055

Compare Adaptimmune (United Kingdom) with another company

Former names

  • Adaptimmune LtdOct 2, 2014 to Mar 17, 20154

Timeline

  1. 2008Founded Founded1

Recent filings

  1. Apr 22, 2026RW
  2. Feb 17, 2026SCHEDULE 13G
  3. Nov 14, 2025SCHEDULE 13G/A
  4. Nov 14, 2025EFFECT
  5. Nov 13, 202515-12G
  6. Nov 13, 2025424B3
  7. Oct 28, 202525
  8. Oct 28, 2025POS AM
  9. Oct 28, 2025S-8 POS
  10. Oct 28, 2025S-8 POS
  11. Oct 28, 2025S-8 POS
  12. Oct 20, 20258-K
  13. Oct 8, 20253 OWNERSHIP DOCUMENT
  14. Sep 26, 20258-K
  15. Sep 12, 20258-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12